Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases.
Adequate balance sheet with concerning outlook.
Share Price & News
How has Chembio Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CEMI's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: CEMI exceeded the US Medical Equipment industry which returned -7.7% over the past year.
Return vs Market: CEMI exceeded the US Market which returned -11.5% over the past year.
Price Volatility Vs. Market
How volatile is Chembio Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StChembio Diagnostics, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know
3 weeks ago | Simply Wall StChembio Diagnostics, Inc. (NASDAQ:CEMI) Insiders Have Been Selling
1 month ago | Simply Wall StThe Chembio Diagnostics (NASDAQ:CEMI) Share Price Is Down 42% So Some Shareholders Are Getting Worried
Is Chembio Diagnostics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CEMI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CEMI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CEMI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: CEMI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CEMI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CEMI is overvalued based on its PB Ratio (4.1x) compared to the US Medical Equipment industry average (3x).
How is Chembio Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CEMI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CEMI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CEMI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CEMI's revenue (12.1% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: CEMI's revenue (12.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CEMI's Return on Equity is forecast to be high in 3 years time
How has Chembio Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CEMI is currently unprofitable.
Growing Profit Margin: CEMI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CEMI is unprofitable, and losses have increased over the past 5 years at a rate of -24.9% per year.
Accelerating Growth: Unable to compare CEMI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CEMI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).
Return on Equity
High ROE: CEMI has a negative Return on Equity (-56.9%), as it is currently unprofitable.
How is Chembio Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: CEMI's short term assets ($32.2M) exceed its short term liabilities ($6.4M).
Long Term Liabilities: CEMI's short term assets ($32.2M) exceed its long term liabilities ($25.3M).
Debt to Equity History and Analysis
Debt Level: CEMI's debt to equity ratio (74.2%) is considered high.
Reducing Debt: Insufficient data to determine if CEMI's debt to equity ratio has reduced over the past 5 years.
Inventory Level: CEMI has a high level of physical assets or inventory.
Debt Coverage by Assets: CEMI's debt is covered by short term assets (assets are 1.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CEMI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CEMI has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -35.6% each year.
What is Chembio Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CEMI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CEMI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CEMI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CEMI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CEMI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Richard Eberly (58yo)
Mr. Richard L. Eberly serves as the President and Chief Executive Officer at Chembio Diagnostics, Inc. since March 16, 2020. He served as the Managing director at Solid Rock Principled Capital where he was ...
|Executive VP & CFO||2.25yrs||US$647.40k||0.26% $257.1k|
|Chief Science and Technology Officer & Executive VP||16.17yrs||US$812.65k||0.61% $609.1k|
|President||no data||no data||no data|
|Senior VP & COO||3.17yrs||no data||0.12% $116.1k|
|Vice President of Corporate Development||1.67yrs||no data||no data|
|Senior VP & Chief Commercial Officer||3.42yrs||US$271.10k||0.085% $84.0k|
|Research Director of Chembio Diagnostic Systems Inc||no data||US$106.37k||no data|
Experienced Management: CEMI's management team is considered experienced (3.2 years average tenure).
|Independent Director||1.58yrs||US$207.58k||0.044% $43.5k|
|Former President||2.67yrs||US$25.00k||0.17% $167.0k|
|Independent Director||1.83yrs||US$167.55k||0.21% $211.5k|
|Chair of the Board||6yrs||US$75.00k||0.51% $504.8k|
Experienced Board: CEMI's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.5%.
Chembio Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Chembio Diagnostics, Inc.
- Ticker: CEMI
- Exchange: NasdaqCM
- Founded: 1985
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$99.308m
- Shares outstanding: 17.73m
- Website: https://chembio.com
Number of Employees
- Chembio Diagnostics, Inc.
- 555 Wireless Boulevard
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CEMI||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Oct 2000|
|D9IA||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||Oct 2000|
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/29 02:44|
|End of Day Share Price||2020/03/27 00:00|